| PEGylation, successful approach to drug delivery FM Veronese, G Pasut Drug discovery today 10 (21), 1451-1458, 2005 | 2913 | 2005 |
| State of the art in PEGylation: the great versatility achieved after forty years of research G Pasut, FM Veronese Journal of controlled release 161 (2), 461-472, 2012 | 819 | 2012 |
| Polymer–drug conjugation, recent achievements and general strategies G Pasut, FM Veronese Progress in polymer science 32 (8-9), 933-961, 2007 | 778 | 2007 |
| PEG conjugates in clinical development or use as anticancer agents: an overview G Pasut, FM Veronese Advanced drug delivery reviews 61 (13), 1177-1188, 2009 | 564 | 2009 |
| Polyoxazoline: chemistry, properties, and applications in drug delivery TX Viegas, MD Bentley, JM Harris, Z Fang, K Yoon, B Dizman, R Weimer, ... Bioconjugate chemistry 22 (5), 976-986, 2011 | 473 | 2011 |
| PEG− doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity FM Veronese, O Schiavon, G Pasut, R Mendichi, L Andersson, A Tsirk, ... Bioconjugate chemistry 16 (4), 775-784, 2005 | 430 | 2005 |
| Synthesis and characterization of poly (2-ethyl 2-oxazoline)-conjugates with proteins and drugs: suitable alternatives to PEG-conjugates? A Mero, G Pasut, L Dalla Via, MWM Fijten, US Schubert, R Hoogenboom, ... Journal of Controlled Release 125 (2), 87-95, 2008 | 261 | 2008 |
| Antitumoral activity of PEG–gemcitabine prodrugs targeted by folic acid G Pasut, F Canal, L Dalla Via, S Arpicco, FM Veronese, O Schiavon Journal of Controlled Release 127 (3), 239-248, 2008 | 219 | 2008 |
| Protein, peptide and non-peptide drug PEGylation for therapeutic application G Pasut, A Guiotto, FM Veronese Expert Opinion on Therapeutic Patents 14 (6), 859-894, 2004 | 193 | 2004 |
| Anti-cancer PEG-enzymes: 30 years old, but still a current approach G Pasut, M Sergi, FM Veronese Advanced drug delivery reviews 60 (1), 69-78, 2008 | 185 | 2008 |
| Polyethylene glycol (PEG)-dendron phospholipids as innovative constructs for the preparation of super stealth liposomes for anticancer therapy G Pasut, D Paolino, C Celia, A Mero, AS Joseph, J Wolfram, D Cosco, ... Journal of controlled release 199, 106-113, 2015 | 160 | 2015 |
| Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol G Pasut BioDrugs 28 (Suppl 1), 15-23, 2014 | 136 | 2014 |
| Dendritic poly (ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms C Clementi, K Miller, A Mero, R Satchi-Fainaro, G Pasut Molecular pharmaceutics 8 (4), 1063-1072, 2011 | 133 | 2011 |
| PEGylation of proteins as tailored chemistry for optimized bioconjugates G Pasut, FM Veronese Polymer Therapeutics I, 95-134, 2006 | 132 | 2006 |
| PEG–Ara-C conjugates for controlled release O Schiavon, G Pasut, S Moro, P Orsolini, A Guiotto, FM Veronese European journal of medicinal chemistry 39 (2), 123-133, 2004 | 126 | 2004 |
| Site-specific pegylation of G-CSF by reversible denaturation FM Veronese, A Mero, F Caboi, M Sergi, C Marongiu, G Pasut Bioconjugate chemistry 18 (6), 1824-1830, 2007 | 123 | 2007 |
| The pentose phosphate pathway and its involvement in cisplatin resistance I Giacomini, E Ragazzi, G Pasut, M Montopoli International journal of molecular sciences 21 (3), 937, 2020 | 105 | 2020 |
| Selective conjugation of poly (2-ethyl 2-oxazoline) to granulocyte colony stimulating factor A Mero, Z Fang, G Pasut, FM Veronese, TX Viegas Journal of controlled release 159 (3), 353-361, 2012 | 104 | 2012 |
| PEGylation for improving the effectiveness of therapeutic biomolecules. G Pasut, FM Veronese Drugs of Today (Barcelona, Spain: 1998) 45 (9), 687-695, 2009 | 103 | 2009 |
| Novel monodisperse PEG− dendrons as new tools for targeted drug delivery: synthesis, characterization and cellular uptake M Berna, D Dalzoppo, G Pasut, M Manunta, L Izzo, AT Jones, R Duncan, ... Biomacromolecules 7 (1), 146-153, 2006 | 102 | 2006 |
